



Quotient  
Sciences  
Assess. Adapt. Accelerate.

**FOR IMMEDIATE RELEASE**

**CONTACTS:**

Jane Byram for Quotient Sciences  
SCORR Marketing  
512-626-2758  
jane@scormarketing.com

Kelley Skoloda for CytoAgents  
KS Consulting & Capital  
412-897-3369  
kelley.skoloda@ksconsultingandcapital.com

**Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm**

**Collaboration Expedites Human Clinical Trials for COVID-19 Drug Candidate**

**NOTTINGHAM, U.K., and PITTSBURGH, April 28, 2020** – A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by [Quotient Sciences](#), a leading provider of innovative drug development and manufacturing solutions, and [CytoAgents, Inc.](#), a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases. The partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in 2020.

Scientific consensus is building that severe illness caused by COVID-19 and other infectious diseases is triggered by a phenomenon known as “cytokine storm,” an excessive immune response that attacks the body. GP1681 is a small molecule inhibitor of cytokine release in activated human immune cells and has been shown to safely modulate the natural immune response by tamping down various cytokines. GP1681 addresses an unmet need for therapeutic treatment by targeting the underlying cause of life-threatening symptoms associated with cytokine storm, which can cause more harm than the virus itself.

“Our mission is to create a powerful, lasting solution, not just for the current crisis but for any respiratory epidemic, thereby saving lives and reducing the strain on healthcare facilities,” said [Teresa Whalen, RPh](#), CEO, CytoAgents. “Working with Quotient Sciences is a major milestone for CytoAgents in its accelerated path for a universal treatment for COVID-19-related or any respiratory epidemic.”

[Mark Egerton, Ph.D.](#), CEO, Quotient Sciences, said, “The COVID-19 pandemic has caught humanity off guard, and we need to act swiftly to bring new medicines to patients around the world. We are delighted to support CytoAgents with the product development of GP1681.”

Under the scope of the agreement, CytoAgents will access Quotient’s formulation and manufacturing expertise to develop and rapidly supply drug product for Phase I and II testing in 2020. In parallel, Quotient will work to develop a scalable solid oral dosage form for larger patient trials and commercialization. The program will be conducted at Quotient’s facility in Garnet Valley, PA, which has specialized drug handling and containment suitable for highly potent drug candidates.

### **About Quotient Sciences**

Quotient Sciences is an innovative global pharmaceutical development, clinical and commercial manufacturing organization providing services to the pharmaceutical and biotech industries. A combination of specialized skills and agile integrated processes enables Quotient Sciences to develop customized solutions which dramatically reduce the time and cost of getting drugs to market. Everything we do is driven by a deeply held belief, shared across the entire organization, that molecules need to become cures — fast.

### **About CytoAgents**

CytoAgents is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, influenza, viral infectious diseases and conditions that cause acute respiratory distress. Using a novel, host-directed approach, our lead compound, GP1681, targets the underlying cause of life-threatening respiratory distress, cytokine release syndrome, by modulating the body’s natural immune response to sickness or disease. We are committed to developing first-in-class, best-in-class products that meet a major medical need now and into the future.